Julie Vose, MD
Hematology & Oncology · Omaha, NENPI 1598717845
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $111,266 of the $122,673 with a category attached, or 90.7%. It is spread thinly across 29 manufacturers, the largest accounting for just 18.5%. Reporting peaked in 2020 at $26,325 and has fallen 74.9% since, to $6,596 in 2025. Among hematology & oncology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $1264.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$23K
- AbbVie$18K
- Eli Lilly$10K
- Genentech, Inc.$9K
- Genmab U.S., Inc.$9K
- Novartis$7K
- plus $47K from 23 others
Across 239 payments — averaging $14,236 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genmab U.S., Inc.$1.1M
- Gilead$448K
- Bristol Myers Squibb$436K
- Eli Lilly$324K
- Epizyme, Inc.$283K
- AbbVie$247K
- plus $569K from 7 others
What the payments were for
- Consulting fees$111,26691%
- Speaking & faculty fees$2,6002%
- Travel & lodging$6,5785%
- Food & beverage$2,0472%
- Education$1820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $22,654 |
| AbbVie | 16 | $18,496 |
| Eli Lilly | 4 | $9,737 |
| Genentech, Inc. | 3 | $8,910 |
| Genmab U.S., Inc. | 10 | $8,748 |
| Novartis | 5 | $7,287 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $7,200 |
| Verastem, Inc. | 1 | $6,525 |
| Merck | 2 | $5,795 |
| Genentech USA, Inc. | 2 | $3,622 |
| Seagen Inc. | 3 | $3,246 |
| Incyte Corporation | 3 | $2,925 |
| Johnson & Johnson | 3 | $2,897 |
| Janssen Scientific Affairs, LLC | 1 | $2,170 |
| Gilead(2 entities) | 2 | $1,704 |
| Beone Medicines USA, Inc. | 2 | $1,617 |
| Karyopharm Therapeutics Inc. | 1 | $1,600 |
| Lilly USA, LLC | 1 | $1,600 |
| Astrazeneca UK Limited | 1 | $1,370 |
| Bayer | 1 | $1,260 |
| BTG International Inc. | 2 | $1,068 |
| Daiichi Sankyo Inc. | 1 | $968 |
| Kyowa Kirin, Inc. | 1 | $770 |
| Ipsen Biopharmaceuticals, Inc | 3 | $182 |
| Epizyme, Inc. | 2 | $102 |
| Acerta Pharma LLC | 1 | $73 |
| E.r. Squibb & Sons, L.L.C. | 1 | $71 |
| Puma Biotechnology, Inc. | 1 | $60 |
| Morphosys, US Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,673 in reported general payments places this provider in the 90th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 80 | $979,226 |
| ImbruvicaIbrutinib | 52 | $786,228 |
| VenclextaVenetoclax | 51 | $688,806 |
| CalquenceAcalabrutinib Maleate | 34 | $439,940 |
| JaypircaPirtobrutinib | 13 | $249,173 |
| EliquisApixaban | 24 | $14,030 |
| BexseroMeningococcal B Vaccine,4-Comp | 11 | $2,297 |
| Acyclovir | 83 | $1,543 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 84 | $570 |
| PedvaxhibHaemph B Polysac Conj-Menin/Pf | 18 | $531 |
| IpolPoliomyelitis Vaccine, Killed | 12 | $490 |
| Infanrix DtapDiph,pertuss(Acell),tet Ped/Pf | 12 | $332 |
| Ondansetron OdtOndansetron | 24 | $330 |
| Gabapentin | 17 | $303 |
| MethotrexateMethotrexate Sodium | 11 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $7,200 | $786,22852 claims |
| AbbVieVenclexta | $18,496 | $688,80651 claims |
| AstraZenecaCalquence | $22,654 | $439,94034 claims |
| Lilly USA, LLCJaypirca | $1,600 | $249,17313 claims |
| MerckPedvaxhib | $5,795 | $53118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
- Marcel DevettenOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.